Coronavirus Notebook: Pfizer/BioNTech & Russian Vaccines Each Claim Efficacy Of More than 90%
Executive Summary
As data start to come in on the first coronavirus vaccines, hopes are rising that vaccination campaigns will be able to begin in the next month or two, although experts have cautioned against unbridled optimism. Uncertainties also remain over questions such as whom to vaccinate first and how to assure equitable access in less wealthy parts of the world.
You may also be interested in...
Coronavirus Update: Moderna Ready For Interim Analysis, Brazil Resumes SinoVac Trial
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
EU May Disclose Some Details Of COVID-19 Vaccine Contracts
The European Commission seems to be prepared to disclose some parts of the contracts it is signing with companies for coronavirus vaccines, but transparency campaigners say this might not be enough to engender trust in the vaccines among the population at large.
Covid-19 Vaccine: UK Experts Caution Against Hopes Of ‘Return To Normal’
The Pfizer/BioNTech coronavirus vaccine results are a cause for celebration, but there is still a long way to go. Safety data are still awaited, as is more information on efficacy, and the mass rollout of the vaccine will pose significant practical challenges.